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Abstract
Background: Fibrates are used especially in patients with hypertriglyceridaemia, a feature of the metabolic
syndrome. Elevated LFTs are often observed in these patients perhaps related to fatty infiltration.
Aim: We wished to study changes seen in LFTs (GGT, ALT and ALP) following fibrate therapy and then determine
associated factors.
Methods: This was a retrospective observational study in which data was collected from case notes of patients
started on fibrates (n = 118, 2002–2008) in the lipid clinic at Good Hope Hospital and pre/post-fibrate lipid and LFT
values were obtained. All biochemistry was performed on the Roche P-Unit using supplied reagents. Statistical
analyses included t tests and regression analyses (factorised when quartiles were compared).
Results: Of the study population 106 patients were on fenofibrate; the remaining on bezafibrate. Significant
lowering of GGT (p < 0.0001), ALT (p = 0.0014) and ALP (p < 0.0001) levels were observed following fibrate
treatment. Baseline lipid (cholesterol, triglycerides and HDL) concentrations, alcohol intake, length of treatment,
gender, concurrent statin treatment and diabetes did not correlate with these changes in LFT in a multiple regression
analysis. Higher pre-fibrate GGT (p < 0.0001), ALT (p < 0.0001) and ALP (p < 0.0001) concentrations were associated
with larger decreases in each of these tests respectively with the highest 2 quartiles (GGT > 57 IU/l, ALT > 34 IU/l and
ALP > 94 IU/l) significantly different to the lowest quartile. The above associations remained significant even when the
regression analyses were corrected for changes in lipid values (which did not show an association).
Conclusions: Fibrate treatment led to improvements in LFT, the greatest benefit seen in patients with higher
baseline LFT values. It appears that baseline and changes in lipid values post fibrate treatment were not associated
with change in LFT.
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Introduction
Fibrates are drugs that are often used to treat patients
with the atherogenic lipoprotein phenotype, charac-
terised by increased triglyceride levels and decreased
levels of HDL-C (Staels et al., 1998a). This pattern of
dyslipidaemia, central weight distribution, hypertension,
and impaired fasting glucose/diabetes are characteristics
of the metabolic syndrome. A decrease of 20–50% in
serum triglyceride levels and an increase of 10–20% in
HDL-C levels have been demonstrated in various studies
following fibrate therapy (Brown et al., 1986; Farnier
et al., 1994; Munoz et al., 1999; Poulter, 1999; Kiortsis
et al., 2000). In contrast with the significant cardiovascu-
lar benefit consistently observed in statin trials (4S (The
Scandinavian Simvastatin Survival Study, 1994), WOS-
COPS (Shepherd et al., 1995), HPS (Heart Protection
Study Collaborative Group, 2002), JUPITER (Ridker
et al., 2008)), only VAHIT (Rubins et al., 1999) and HHS
(Frick et al., 1987) of the fibrate trials have resulted in a
significant reduction in primary outcome. However, sub-
group analysis of all the fibrate trials (VAHIT (Rubins
et al., 1999), HHS (Frick et al., 1987), ACCORD (AC-
CORD Study Group, 2010), BIP (The Bezafibrate Infarc-
tion Prevention (BIP) study, 2000) and FIELD (Keech
et al., 2005)) and a meta-analysis by Jun et al (2010) have
suggested that cardiovascular benefits appear to be
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maximal in subjects possessing characteristics of the
metabolic syndrome.
Patients with the metabolic syndrome and uncon-
trolled dyslipidaemia of long duration are considered to
be at greater risk of developing hepatic steatosis (March-
esini et al., 2001). A two or three hit hypothesis has been
proposed: damage initially caused by fatty infiltration as-
sociated with insulin resistance and obesity; the “first
hit”. This is followed by injury resulting from mecha-
nisms linked to oxidative stress and impairment of cellu-
lar regeneration; the “second and third hits” (Dowman
et al., 2010). The steatosis could progress through NASH
(non-alcoholic steatohepatitis) and liver fibrosis to liver
cirrhosis. The above spectrum of stages is collectively re-
ferred to as NAFLD (non-alcoholic fatty liver disease).
Zelber-Sagi et al. demonstrated that 71% of patients with
the metabolic syndrome had NAFLD (Zelber-Sagi et al.,
2005). Individuals with NAFLD often have higher levels
of insulin, glucose, TG, ALT, BMI and waist circumfer-
ence. Thus, it is likely that a proportion of the patients
with metabolic syndrome will indeed have some degree
of NAFLD. Clinical features of NAFLD include hepato-
megaly and moderate elevation in liver enzymes; includ-
ing GGT and ALT, with steatosis often detected on
ultrasound scanning (Franzini et al., 2012).
Management of NAFLD has focused on improving the
characteristics classifying the metabolic syndrome; weight
management, dyslipidaemia and glycaemia (Chalasani
et al., 2012). As the pathogenesis of NAFLD is related to
insulin resistance and oxidative stress, its therapeutic
management currently includes insulin sensitisers, anti-
oxidants as well as hepatoprotective drugs, which have
shown promise in randomised controlled trials (Belfort
et al., 2006; Harrison et al., 2003; Dufour et al., 2006). Pro-
bucol, an antioxidant, showed improved levels of ALT in
comparison to a placebo over a six-month treatment
period (Merat et al., 2003). Surgical intervention in pa-
tients who are morbidly obese, have shown to improve
transaminases levels post-bariatric surgery (Mathurin
et al., 2009). More research is required into these treat-
ments to prove their efficacy.
Fibrate treatment has been associated with elevated
transaminases. (AST and ALT) and this association ap-
pears to be dose related (Kobayashi et al., 2009). It is rec-
ommended that regular monitoring of liver function be
carried out during fibrate therapy and the drug discon-
tinued if levels persisted above ×3 the upper limit of the
normal reference range (http://www.medicines.org.uk/
emc/medicine/22425/SPC#UNDESIRABLE_EFFECTS).
Fernandez-Miranda et al. carried out a pilot trial evaluating
the effects of fenofibrate in 16 patients with NAFLD for 48
weeks (Fernandez-Miranda et al., 2008). Although signifi-
cant improvement was observed in LFT and the meta-
bolic syndrome, changes in liver histology was minimal.
Interestingly no significant change in BMI was noted that
could have been associated with the changes in LFT.
The dyslipidaemia clinics run at Good Hope Hospital
(part of the Heart of England NHS Foundation Trust)
have used fibrates in patients with severe hypertriglyceri-
daemia and those with the atherogenic lipoprotein
phenotype, the dyslipidaemia seen in the metabolic syn-
drome. Many of these patients had elevated baseline
LFT and regular monitoring was carried out in view of
the association with elevation of transaminases. We
wished to determine whether significant changes in LFT,
such as observed in the study by Fernandez-Miranda
(Fernandez-Miranda et al., 2008) took place following
fibrate therapy and in the event of changes, establish as-
sociated predictive factors.
Methods
This was a retrospective observational study. All patients
commenced on fibrates between 2002 and 2008 in the
lipid clinic at Good Hope Hospital, (Birmingham, United
Kingdom) were included in the study. In all cases the de-
cision to commence fibrate treatment was made on clin-
ical grounds taking current evidence and individual lipid
profile into consideration. Our cohort of 118 patients
was identified from the electronic record database by
using the keywords relevant to this study. All the pa-
tients fulfilled the metabolic syndrome diagnostic criteria
(NCEP/ATPIII) (ATP3/NCEP definition (Expert Panel on
Detection, Evaluation, and Treatment of High Blood Chol-
esterol in Adults), 2001). Table 1 demonstrates that 60 pa-
tients (52.6%) were already on statin treatment and there
were no significant differences in baseline ALT and GGT
as compared to those not on statins. There was however a
small but significant difference in ALP levels in patients
on statins (87.4 IU/L) and those not on statins (76.2 IU/L),
p = 0.03. Increased ALP activity has been previously re-
ported with statin treatment (Walter et al., 2013).
Data for the study was obtained from patient notes
and electronic results documentation (Table 1; this also
demonstrates the scale of missing data). It should be
noted that all our patients received lifestyle management
advice prior to drug treatment being considered. All pa-
tients had pre-fibrate treatment levels of TC, TG, HDL-
C, creatinine, GGT, ALT and ALP measured. The post-
treatment levels obtained were the most current results
available (single determinants) or the results prior to
introduction of another drug/discontinuation of the
fibrate. As 88% of patients were on fenofibrate 160 mg
we could not study the dose response phenomena on
LFT change.
All biochemistry was performed on the Roche P-Unit
using supplied reagents. The data was entered on a
Microsoft Excel spreadsheet and transferred to the
STATA (version 8.0 for Windows) statistical analysis
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software. Paired t-test was carried out to study changes
in LFT (GGT, ALT and ALP) following fibrate treatment
and differences between the cohorts stratified by differ-
ent characteristics (e.g. patients on statins/not on sta-
tins). Separate linear regression analyses were then
performed with changes in LFT (GGT, ALT and ALP) as
the dependent variables and baseline characteristics and
changes in lipids as the independent variables (model 1
of Tables 2, 3 and 4). It was possible that co-linearity
existed between some of the above factors. Thus, inde-
pendence was established by entering all the significant
factors as independent variables in a multivariate regres-
sion analyses (model 2 of Tables 2, 3 and 4).
Results
Most of our patients (106 of 118; 89.8%) were on fenofi-
brate, whilst the remainder was on bezafibrate. Table 1
shows the general characteristics of the cohort and
values for all relevant biochemical markers both pre and
post-fibrate treatment irrespective of gender, smoking
status, alcohol intake, diabetes status and concurrent
statin treatment. Significant changes were seen in TC,
TG and HDL-C following fibrate treatment. These findings
were anticipated as our patient group was a subset of the
cohort previously reported regards the above analytes
(Ramachandran et al., 2012; Abbas et al., 2012). All three
LFT studied decreased (Table 1) with fibrate treatment with
paired t-Test showing the changes to be significant; GGT
(p < 0.0001), ALT (p = 0.0014) and ALP (p < 0.0001).
Factors associated with changes in LFT following fibrate
treatment
We now wished to determine factors associated with the
changes observed above in separate regression analyses.
Table 1 Characteristics of the patient group studied
N % Mean (SD) Median Range
Age 118 52.9 (10.3) 53.2 32.3–72.5
Males 76 68.5
Females 35 31.5
Duration of treatment (years) 110 0.5 (0.4) 0.3 0.02–2.1
Diabetes 31 28.2
On concurrent statin treatment 60 52.6
Never smoked 15 13.8
Ex-smokers 77 70.6
Current smokers 17 15.6
Alcohol (units/week)
0 16 16.8
1–28 55 57.9
>28 24 25.8
Pre-fibrate treatment
TC (mmol/l) 117 6.8 (2.6) 6.1 3.4–20.2
TG (mmol/l) 118 7.3 (7.8) 5.1 1.4–58.1
HDL-C (mmol/l) 98 1.1 (0.2) 1.1 0.7–1.9
Creatinine (μmol/l) 109 84.1 (16.8) 84 33–127
GGT (IU/l) 118 79.2 (59.8) 57.5 13–274
ALT (IU/l) 116 43.1 (33.5) 33.5 9–249
ALP (IU/l) 118 81.2 (24.2) 77.5 34–177
Post-fibrate treatment
TC (mmol/l) 118 5.8 (1.4) 5.6 3–11.2
TG (mmol/l) 118 3.7 (3.8) 2.7 0.8–34.4
HDL-C (mmol/l) 115 1.2 (0.3) 1.1 0.6–2.5
Creatinine (μmol/l) 115 95.1 (20.0) 92 59–143
GGT (IU/l) 116 57.1 (43.6) 42 13–307
ALT (IU/l) 116 37.5 (24.5) 30 12–154
ALP (IU/l) 118 62.0 (19.9) 59 23–147
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The change in LFT (GGT, ALT and ALP) were
dependent variables with age, gender, duration of fibrate
treatment, pre-treatment lipids (TC, TG and HDL-C),
changes in lipids (TC, TG and HDL-C), statin treatment
and pre-treatment LFT (GGT, ALT and ALP) entered as
independent variables.
Change in GGT levels
Male gender, pre-treatment TC, pre-treatment TG, pre-
treatment GGT, pre-treatment ALT, treatment duration
and change in HDL-C were all significantly associated
with changes in GGT (Table 2: Model 1). Multiple regres-
sion analysis (Table 2: Model 2) showed that only pre-
treatment GGT levels (p < 0.001) remained significant.
Change in ALT levels
Table 3: model 1 shows that pre-treatment GGT (p <
0.001) and pre-treatment ALT (p < 0.001) were associated
with changes in ALT following fibrate treatment. Pre-
treatment ALT levels remained significant (p < 0.001)
when both factors were entered in a multiple regression
model.
Change in ALP levels
Table 4: Model 1 shows that pre-treatment GGT (p = 0.04),
pre-treatment ALP (p < 0.001), statin treatment (p = 0.028)
and treatment duration (p = 0.022) were significantly asso-
ciated with changes observed in ALP following fibrate
treatment. Only pre-treatment ALP (p < 0.001) remained
significant on multiple regression.
Association between LFT changes following fibrate and
pre-treatment LFT
We have demonstrated that improvements in GGT, ALT
and ALP were associated with fibrate therapy. The best
predictor of this improvement appears to be the pre-
treatment level of that particular analyte (GGT, ALT and
ALP). The coefficients obtained from the regression ana-
lyses suggested that patients with higher baseline
Table 2 Association between baseline factors and change
in GGT following fibrate treatment
Model 1: linear regression analysis with change in GGT as the
dependent variable and the following as independent variables in
separate analyses
n Co-efficient 95% C.I. p-value
Gender (male) 116 −21.04 −37..03- –5.06 0.010
Pre-TC 115 −3.28 −6.18- –0.38 0.027
Pre-TG 116 −1.08 −2.03- –0.14 0.025
Pre fibrate GGT 116 −0.47 −0.56- –0.38 <0.001
Pre fibrate ALT 114 −0.28 −0.51- –0.05 0.0180
Treatment duration 117 19.7 1.35-38.0 0.036
change in HDL-C 98 −33.79 −57.19- –10.38 0.005
Model 2: multiple regression analysis with change in GGT as the
dependent variable and the following as independent variables in a
single analysis.
n Co-efficient 95% C.I. p-value
Gender (male) 96 (r2 = 0.52) −5.47 −18.77-7.83 0.42
Pre-TC 0.48 −3.81-4.77 0.83
Pre-TG −1.43 −3.77-0.91 0.23
Pre fibrate GGT −0.44 −0.56- –0.31 <0.001
Pre fibrate ALT 0.07 −0.12-0.26 0.48
Treatment duration 12.5 1.86-26.9 0.087
change in HDL-C −24.61 −55.42-6.22 0.12
Age, pre-fibrate HDL-C, pre-fibrate ALP, pre-fibrate creatinine, change in TC,
change in TG were not significantly associated with changes observed in GGT
following fibrate treatment.
Table 3 Association between baseline factors and change
in ALT following fibrate treatment
Model 1: linear regression analysis with change in ALT as the
dependent variable and the following as independent variables in
separate analyses
n Co-efficient 95% C.I. p-value
Pre fibrate GGT 114 −0.1 −0.15- –0.05 <0.001
Pre fibrate ALT 114 −0.36 −0.43- –0.28 <0.001
Model 2: multiple regression analysis with change in ALT as the
dependent variable and the following as independent variables in a
single analysis.
n Co-efficient 95% C.I. p-value
Pre fibrate GGT 114 (r2 = 0.45) −0.03 −0.08-0.012 0.16
Pre fibrate ALT −0.33 −0.41- –0.25 <0.001
Age, gender, pre-fibrate lipids (TC, TG & HDL-C), pre-fibrate ALP, pre-fibrate
creatinine, treatment duration and changes in lipids (TC, TG & HDL-C) were
not significantly associated with changes observed in ALT following
fibrate treatment.
Table 4 Association between baseline factors and change
in ALP following fibrate treatment
Model 1: Linear regression analysis with change in ALP as the
dependent variable and the following as independent variables in
separate analyses
n Co-efficient 95% C.I. p-value
Pre-fibrate GGT 118 −0.02 −0.10- –0.002 0.04
Pre-fibrate ALP 118 −0.38 −0.48- –0.28 <0.001
Treatment duration 117 6.36 0.92-11.81 0.022
Statin treatment 118 6.63 0.75-12.5 0.028
Model 2: Multiple regression analysis with change in ALP as the
dependent variable and the following as independent variables in
single analysis
n Co-efficient 95% C.I. p-value
Pre-fibrate GGT 117 (r2 = 0.33) 0 −0.04-0.04 0.96
Pre-fibrate ALP 0.36 0.26-0.47 <0.001
Treatment duration −4.56 −9.18-0.07 0.054
Statin treatment 2.00 −3.08-7.08 0.44
Age, gender, diabetes, pre-fibrate lipids (TC, TG & HDL-C), pre-fibrate ALT,
pre-fibrate creatinine, changes in lipids (TC, TG & HDL-C) were not significantly
associated with changes observed in ALP following fibrate treatment.
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concentrations were more likely to see greater decreases
in the respective LFT following fibrate treatment.
We wished to further characterise this observation. Pa-
tients were stratified into quartiles based on the pre-
treatment GGT, ALT and ALP and the changes seen in
these analytes presented in Figure 1. Details of the quar-
tiles for each of the LFT (pre-treatment range and de-
tails of the change observed (mean and median) are
presented in the figure. Regression analyses were per-
formed with changes in GGT, ALT and ALP as dependent
variables in separate analyses with pre-treatment GGT,
ALT and ALP now factorised; in the previous regression
analyses they were continuous variable. Quartile 1 was
considered as the reference category and the other quar-
tiles compared to this (Figure 1). The quartiles 3 and 4
(GGT ≥ 56 IU/l, ALT ≥ 34 IU/l and ALP ≥ 77 IU/l) were
significantly different to the reference quartile 1 in each of
the regression models. The above associations remained
significant even when the regression analyses were cor-
rected for changes in lipid values (which were not signifi-
cantly associated themselves).
Discussion
Our study suggested improvements in GGT, ALT and ALP
following fibrate treatment. The decrease of each of these
enzymes was greater in patients with higher baseline values.
NAFLD/NASH is a common feature of the metabolic syn-
drome. As all our patients had dyslipidaemia characteristic
of the metabolic syndrome it is reasonable to speculate that
improvements in NAFLD/NASH may have contributed to
improving LFT. However it should be noted that the pre-
cise relationship between abnormal LFTs and NASH out-
comes requires further clarity. To be more certain of our
hypothesis a liver biopsy where fat content can be directly
measured would have to be carried out before and after
treatment. This is not currently part of our routine clinical
management. Other investigations such as ultrasound, CT/
MRI scans although useful in confirming the presence of
fat, have limitations (http://www.worldgastroenterology.org/
assets/export/userfiles/2012_NASH%20and%20NAFLD_
Final_long.pdf ). Inadequate sensitivity and specificity to-
gether with an inability to quantify hepatic fat content
restrict the value of these investigations in studies such as
ours. Other hepatic pathology was excluded when clinically
suspected or in patients whose LFT was greater than 5
times the ULN. Investigations here included further bio-
chemistry/immunology as well as serology (viral hepatitis)
and radiology.
The best predictors of LFT decrease appeared to be
the baseline levels of that particular enzyme. Current
views on the pathogenesis of NAFLD/NASH may pro-
vide an explanation. A two hit hypothesis was initially
proposed with accumulation of hepatic fat, possibly as-
sociated with insulin resistance leading to inhibition of
fatty acid oxidation considered the “first hit” (Day and
James, 1998; Day, 2006). Factors that were thought to
constitute the second hit include oxidative stress, mito-
chondrial abnormalities and hormonal imbalance (e.g.
adiponectin and leptin levels). Since then the possibility
of a “third hit”, factors impairing hepatocyte regener-
ation and proliferation has been suggested (Dowman
et al., 2010; Jou et al., 2008).
Fibrates bind PPARα nuclear receptors and following di-
merisation with RXR forms PPRE that in turn regulates
gene transcription (genes regulated include ApoA1,
ApoA2, ApoA5, LPL, ABCA1, ABCG1 and SRB1)
(Auwerx et al., 1996). Increased mitochondrial fatty acid
oxidation has been observed following PPARα activation
in murine studies (Kerten et al., 1999). A functional
PPARα appears to be a prerequisite for fatty acid
Figure 1 Change in LFT following fibrate treatment pre-fibrate LFT stratified as quartiles.
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catabolism and PPARα null mice show elevated free fatty
acids (Aoyama et al., 1998). The liver produces VLDL con-
tinuously from endogenous synthesis, cytosolic TG stores,
plasma lipoproteins and circulating free fatty acids. Thus,
we speculate that fibrates may reduce hepatic fat, the “first
hit” (Day, 2006). PPARα is also expressed in other cells/tis-
sues; endothelium, smooth muscle, monocytes and macro-
phages (Chinetti et al., 1998; Inoue et al., 1998; Staels
et al., 1998b). It may play a role in inhibition of inducible
nitric oxide synthase gene transcription in macrophages
thereby limiting inflammation (Paukkeri et al., 2007). Ani-
mal studies have also suggested this, although it must be
stated that the effects of fibrates on murine peroxisomes
varies from that on humans (Doull et al., 1999). This sug-
gests that the effect of the “second hit” may also be limited
(Jou et al., 2008).
Thus, fibrates may have a beneficial effect on both
fatty acid oxidation and inflammation. Due to this we
speculate that improvement in LFT associated with
fibrates may be due to interrupting the pathogenesis of
NAFLD/NASH at various points. In diseases of multifac-
torial aetiology a reduction in the risk posed by individ-
ual factors (e.g. changes in lipid levels following fibrate
treatment) may not predict the changes observed in
LFT. The presence of baseline NAFLD/NASH would be
expected to be a better predictor as it would be associ-
ated with all the causative risk factors. This may be the
reason that baseline LFT (which may be associated with
NAFLD/NASH in our patients with the metabolic syn-
drome) was the best predictor of benefit following
fibrates.
The above points raised are based on the assumption
that the LFT elevation was associated with NAFLD/
NASH. It is followed by a suggestion that the decrease
in LFT levels was due to improvements in NAFLD/
NASH. We accept that these may be considered steps
too far. Regression to the mean is also a possibility.
However, by making the point we would like to see simi-
lar studies in the future, but with confirmation and an
estimate of hepatic fat content via non-invasive radiog-
raphy. Corroboration of Fibroscan/Steatoscan results
with biochemical markers of fibrosis would be interest-
ing in a prospective cohort with a control group.
Very few clinical trials have examined the effects of
fibrates on NAFLD (Nakajima, 2012). Laurin J et al. re-
port no significant change in liver histology or enzymes
(except for ALP) in 16 patients receiving clofibrate ther-
apy for 12 months (Laurin et al., 1996). Basaranoglu M
et al. administered gemfibrozil to 17 patients for 4 weeks
and demonstrated a significant reduction in mean serum
ALT, AST and GGT levels in comparison with the con-
trol group (Basaranoglu et al., 1999). The most recent
clinical study in the literature examining the effects of
fibrates on NAFLD was a pilot trial by Fernandes-
Miranda in which 16 patients were administered fenofi-
brate for 48 weeks (Fernandez-Miranda et al., 2008). A
significant decrease in abnormal LFT was noted com-
pared to the control group although liver histology did
not change significantly. Our study is the largest to date
examining the effect of fibrates on LFT and also the first
to demonstrate any association linked with this effect.
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